MEDIA_REFRESH_DATA_PRESS_RELEASE
Media
U.S. News Room
Press Releases
Mon Apr 21 00:00:00 GMT-05:00 2025
NEW
ENHERTU® Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer
Download
Mon Mar 31 00:00:00 GMT-05:00 2025
DESTINY-Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer
Download
Mon Mar 03 00:00:00 GMT-05:00 2025
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with HER2 Positive Metastatic Gastric Cancer at Interim Analysis of DESTINY-Gastric04 Phase 3 Trial
Download
Thu Jan 30 00:00:00 GMT-05:00 2025
Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer
Download
Thu Jan 30 00:00:00 GMT-05:00 2025
TROPION-Lung12 Phase 3 Trial Initiated Evaluating DATROWAY® as Part of Adjuvant Regimen for Patients with Early-Stage Non-Small Cell Lung Cancer at High Risk of Relapse
Download
Mon Jan 27 00:00:00 GMT-05:00 2025
ENHERTU® Approved in the U.S. as First HER2 Directed Therapy for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following Disease Progression After One or More Endocrine Therapies
Download
Tue Jan 21 00:00:00 GMT-05:00 2025
Daiichi Sankyo Establishes “Smart” Research Laboratory in San Diego to Expedite Drug Discovery
Download
Fri Jan 17 00:00:00 GMT-05:00 2025
DATROWAY® Approved in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
Download
Mon Jan 13 00:00:00 GMT-05:00 2025
Daiichi Sankyo Acquires Intellectual Property Rights for Anti-TA-MUC1 Antibody in DS-3939 from Glycotope GmbH
Download